Inventor, researcher, academician, entrepreneur, to discover and bring novel first-in-class medicines for critically ill patients. Chairman and CEO of Pharmazz
Willowbrook, IL USA
Joined August 2013
- Tweets399
- Following39
- Followers293
- Likes185
Pinned Tweet
From India to the World: The Rise of Sovateltide in Stroke Recovery fehealthcare.financialexpres…
3
123
The Story of Sovateltide: Teaching the Brain to Heal youtu.be/yVE4H5k2U0k?si=JF2w… via @YouTube
2
36
We are proud to announce that the U.S. FDA has cleared our Investigational New Drug (IND) application, advancing sovateltide (IRL-1620) into a pivotal Phase III clinical trial for acute traumatic brain injury (TBI). With millions affected annually and zero approved neuroprotective pharmacotherapies available, this milestone marks a critical step forward in addressing one of modern medicine’s greatest unmet needs. By harnessing our proprietary neural repair discovery platform, sovateltide targets the cascade of secondary cell death while stimulating neurogenesis and angiogenesis. Building on the strong momentum of our ongoing global Phase III RESPECT-ETB study in acute ischemic stroke, this clearance further validates the broad therapeutic potential of our endothelin-B receptor platform across severe acute neurovascular conditions. Please read the full announcement here: globenewswire.com/news-relea…
#Biotech #Neuroscience #TraumaticBrainInjury #ClinicalTrials #FDA #Pharmazz #Neuroregeneration
1
5
52
Pharmazz Completes Enrollment in 160-Patient Phase 4 Trial of Sovateltide in Acute Ischemic Stroke globenewswire.com/news-relea…
14
Pharmazz, Inc. Receives U.S. FDA Orphan Drug Designation for Sovateltide for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) globenewswire.com/news-relea…
2
85
On this World Sepsis Day, we reaffirm our commitment to advancing the science of shock management: minimizing fluid overload, protecting end-organ microcirculation, and driving innovation to give every patient a fighting chance at recovery. Resuscitation must move beyond macro-hemodynamic target numbers toward true microcirculatory restoration. Novel pharmacologic strategies, such as centhaquine, can fundamentally shift the shock resuscitation paradigm. Centhaquine (Lyfaquin) acts selectively on venous alpha2B-adrenoceptors to induce venoconstriction. This shifts blood from the large unstressed venous reservoir into the stressed circulation, increasing effective venous return, stroke volume, and cardiac output without worsening cardiac afterload.
Our recent publication provides an important insight into the mechanism of action of centhaquine (Lyfaquin). The article is online @ doi.org/10.1113/EP093743.
#WorldSepsisDay #SepsisAwareness #CriticalCareMedicine #IntensiveCare #Hemodynamics #SepticShock #ClinicalResearch #TranslationalMedicine
Anil Gulati (@ProfessorGulati), inventor and Pharmazz CEO, shares a VJNeurology video on the ongoing Phase III RESPECT-ETB trial (NCT05691244) of sovateltide for acute ischemic stroke, calling it reassuring as the drug's creator.
Sovateltide is an endothelin-B receptor agonist designed to promote neural recovery and regeneration via neuroprogenitor cell effects, already approved and marketed in India as Tyvalzi™ after successful local Phase III and Phase IV studies.
The FDA fast-tracked US trial allows a 24-hour treatment window, includes thrombolysis, and targets patients with NIHSS 8-19, leveraging extensive non-US data showing mRS score improvements.
youtu.be/KOy7HY7S-sg?is=0UqO…
I just came across this video. As an inventor of this technology found it very assuring
3
110
youtu.be/KOy7HY7S-sg?is=0UqO…
I just came across this video. As an inventor of this technology found it very assuring
It is a pleasure to know that all three students working with me have been selected to receive the YOUNG INVESTIGATOR TRAVEL AWARD to attend the Nineteenth International Conference on Endothelin: From New Discoveries to New Treatments (ET-19) that will take place September 21-24, 2025, in Charleston, South Carolina.
1. Preyan Mehta will be presenting his abstract entitled "Systematic Review and Meta-Analysis of Sovateltide, Alteplase, and Tenecteplase Treatments for Acute Cerebral Ischemic Stroke."
2. Emmie Anderson will be presenting her abstract entitled "Sovateltide (IRL-1620), an endothelin B receptor agonist for cerebral ischemic stroke treatment, shows an unexpected reduction in lymphedema in a lymphatic filariasis patient."
3. Vishnu Yelakanti will be presenting his abstract entitled "A Phase III Study to Assess the Safety and Efficacy of Sovateltide in Patients with Acute Cerebral Ischemic Stroke: Protocol of the RESPECT-ETB Trial."
#stroke #cererbal #ischemia #endothelin # sovateltide #travel #award
3
3
73
CHI Memorial First In Region To Enroll Patient In Groundbreaking Stroke Clinical Trial chattanoogan.com/2025/7/31/5…
1
3
64
Press Release
finance.yahoo.com/news/pharm…
1
48
A landmark day for me was yesterday, July 24, 2025, when the First Patient in the USA was enrolled and treated in the Phase 3 RESPECT-ETB (clinicaltrials.gov/study/NCT…) Sovateltide Stroke Trial.
The concept of using Sovateltide in stroke patients was invented in our laboratory. It is a selective ETB receptor agonist that has demonstrated significant benefits over standard care in a prior Phase 3 trial in India.
The RESPECT-ETB Phase 3 trial has an FDA Special Protocol Assessment agreement and will enroll a total of 514 patients with cerebral ischemic stroke at 65 sites across the US, Germany, Spain, Australia, and the UK, with the primary outcome measure being functional independence at 90 days.
#stroke #endothelin #Neurology #sovateltide #pharmazz #brain
45
The University of West Attica, Greece confers an honorary Doctorate. It was an experience to get an honorary doctorate from the University of West Attica, a public university with 65,000 students.
#HonoraryDoctorate
#Greece
#Athens
#Pharmazz
#EmeritusProfessor
2
2
90
Sovateltide: A new drug for stroke patients
link.springer.com/article/10…
A double-blind, placebo-controlled, multicentre, Phase III clinical trial of sovateltide was conducted in participants with cerebral ischaemic stroke receiving standard of care in India.
Sovateltide was well tolerated and effective in improving neurological outcomes, with the proportion of patients with a modified Rankin Scale score (mRS) 0–2 at 90 days being higher in sovateltide than the control group. The ordinal shift in mRS and National Institutes of Health Stroke Scale score across the entire range between control and sovateltide groups was favourable towards sovateltide.
Sovateltide has received regulatory approval for cerebral ischaemic stroke in India, and a larger Phase III trial involving multiple countries is about to begin enrolment (NCT05691244).
#stroke #cerebral #ischemia #endothelin #neurology #pharmazz #AHA #ISC #wsc #WSO